 |
| Novartis' India managing director Ranjit Shahani |
Swiss drug giant Novartis ($NVS) says it has taken "remedial action" to correct problems at two of its plants in western India that were given a warning letter by the U.S. Food and Drug Administration, according to a report by NDTV.
The FDA said the plants had "deficiencies" in their "good manufacturing practices," but the company's managing director for India, Ranjit Shahani, told NDTV that the plants, which are part of Novartis's generic maker Sandoz, have had "remedial action" taken and "would soon be back to normal."
The plants in the state of Maharashtra produce active pharmaceutical ingredients and oral solid dosages, according to the NDTV report.
Novartis officials said in October when the company released its earnings that it would close one of the troubled plants, but did not say which one and also said there were no "supply issues."
- here's the story from NDTV